enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Direct thrombin inhibitor - Wikipedia

   en.wikipedia.org/wiki/Direct_thrombin_inhibitor

   Ximelagatran showed good efficacy compared with warfarin in several trials in prevention and treatment of deep vein thrombosis and as thromboprophylaxis in atrial fibrillation. [1] Development was stopped by manufacturer AstraZeneca , however, because of reports of liver enzyme derangements and liver failure .

3. Apixaban - Wikipedia

   en.wikipedia.org/wiki/Apixaban

   In the EU, apixaban is indicated for the prevention of venous thromboembolic events (VTE) in adults who have undergone elective hip or knee replacement surgery, the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with one or more risk factors, for the treatment of deep vein thrombosis (DVT) and ...

4. Direct factor Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Direct_factor_Xa_inhibitors

   The monitoring of warfarin and keeping the international normalized ratio (INR) between 2.0 and 3.0, along with avoiding over and under treatment, has driven a search for an alternative. [3] [14] A naturally occurring inhibitor of factor Xa was reported in 1971 by Spellman et al. from the dog hookworm. [15]

5. ELIQUIS® (apixaban) Demonstrated Superiority In Reducing A ...

   www.aol.com/news/2012-12-08-eliquis-apixaban...

   AMPLIFY-EXT (Apixaban after the initial Management of PuLmonary embolIsm and deep vein thrombosis with First-line therapY-EXTended Treatment), a randomized, double-blind, multicenter trial ...

6. Adenosine diphosphate receptor inhibitor - Wikipedia

   en.wikipedia.org/wiki/Adenosine_diphosphate...

   The clinically approved dose of prasugrel is a 60-mg loading dose PO and a 10-mg a day maintenance dose PO. [28] Ticagrelor is a much more potent inhibitor of platelet aggregation than clopidogrel, however, it is associated with increase of dyspnoea episodes in patients. These episodes can range from mild to moderate severity.

7. FDA Accepts Eliquis® (apixaban) Supplemental New Drug ... - AOL

   www.aol.com/2013/07/11/fda-accepts-eliquis...

   FDA Accepts Eliquis ® (apixaban) Supplemental New Drug Application for Review for Prophylaxis of Deep Vein Thrombosis Following Hip Or Knee Replacement Surgery PRINCETON, N.J. & NEW YORK ...

8. U.S. FDA Approves ELIQUIS® (apixaban) to Reduce the ... - AOL

   www.aol.com/news/2013-01-02-us-fda-approves...

   U.S. FDA Approves ELIQUIS ® (apixaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation ELIQUIS Demonstrated Superior Risk Reductions Versus ...

9. Discovery and development of direct Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Discovery_and_development...

   Indication for Xa inhibitors is preventing deep vein thrombosis (DVT) which can lead to pulmonary embolism. It is also used to treat atrial fibrillation to lower the risk of stroke caused by a blood clot. Another indication is a prophylactic treatment for blood clotting due to atherosclerosis.